Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/35916
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTocaciu S.en
dc.contributor.authorTasfia Saief S.en
dc.contributor.authorBriggs K.en
dc.contributor.authorBreik O.en
dc.contributor.authorRichardson S.en
dc.date.accessioned2021-05-14T12:09:38Zen
dc.date.available2021-05-14T12:09:38Zen
dc.date.copyright2019en
dc.date.created20190718en
dc.date.issued2019-07-18en
dc.identifier.citationInternational Journal of Oral and Maxillofacial Surgery. 48 (8) (pp 1022-1027), 2019. Date of Publication: August 2019.en
dc.identifier.issn0901-5027en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/35916en
dc.description.abstractOsteoradionecrosis (ORN) is an infrequent but serious complication of radiotherapy, especially in the head and neck region. It is a slowly progressive condition, with management in the early stages focused on symptom control, and surgery usually reserved for advanced ORN. However, established ORN is difficult to treat. The role of hyperbaric oxygen therapy has recently been contested. The use of pentoxifylline in the management of ORN was first described by Delanian in 2004, but its benefits have not been replicated in other studies. In cases of advanced ORN with pathological fractures, many centres still advocate surgical resection and reconstruction. However, in this group of patients who often have multiple medical comorbidities, many of whom have previously undergone significant surgery, a resective plan is not always ideal. This paper presents two successful cases of bony union after the use of pentoxifylline and tocopherol to manage grade III ORN of the mandible. Both patients had pathological fractures and orocutaneous fistulas and were deemed unsuitable for surgery. The possible reasons for the success of pentoxifylline and tocopherol are discussed, and a review of the current literature evidence of similar cases is presented. Pentoxifylline and tocopherol should be considered for the management of advanced ORN where surgical management is not appropriate.Copyright © 2019 International Association of Oral and Maxillofacial Surgeonsen
dc.languageEnglishen
dc.languageenen
dc.publisherChurchill Livingstoneen
dc.relation.ispartofInternational Journal of Oral and Maxillofacial Surgeryen
dc.titleIs there a role for pentoxifylline and tocopherol in the management of advanced osteoradionecrosis of the jaws with pathological fractures? Case reports and review of the literature.en
dc.typeArticleen
dc.type.studyortrialCase series or case report-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1016/j.ijom.2019.03.894en
dc.publisher.placeUnited Kingdomen
dc.identifier.pubmedid30981534 [http://www.ncbi.nlm.nih.gov/pubmed/?term=30981534]en
dc.identifier.source2001796697en
dc.identifier.institution(Breik, Tocaciu, Briggs, Tasfia Saief, Richardson) Oral and Maxillofacial Unit, Monash Health, Victoria, Australia (Breik) Queen Elizabeth Hospital, Birmingham, United Kingdomen
dc.description.addressS. Tocaciu, Oral and Maxillofacial Unit, Monash Health, Victoria, Australia. E-mail: shreyatocaciu@gmail.comen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2019 Elsevier B.V., All rights reserved.en
dc.subect.keywordsORN osteonecrosis osteoradionecrosis PENTO PENTOCLO pentoxifylline radiotherapy tocopherolen
dc.identifier.authoremailTocaciu S.; shreyatocaciu@gmail.comen
item.openairetypeArticle-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.cerifentitytypePublications-
Appears in Collections:Articles
Show simple item record

Page view(s)

46
checked on May 3, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.